- Home
- ABOS
as of 02-09-2026 4:00pm EST
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEWTON |
| Market Cap: | 114.5M | IPO Year: | 2021 |
| Target Price: | $7.50 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.86 - $3.05 | Next Earning Date: | 03-26-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -123745000.0 | FCF Growth: | N/A |
AI-Powered ABOS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Acumen Pharmaceuticals Inc. (ABOS)
Chief Legal Officer & Corp Sec
Avg Cost/Share
$3.00
Shares
2,671
Total Value
$8,017.27
Owned After
173,999
SEC Form 4
Chief Legal Officer & Corp Sec
Avg Cost/Share
$3.00
Shares
15,085
Total Value
$45,262.54
Owned After
173,999
SEC Form 4
Chief Legal Officer & Corp Sec
Avg Cost/Share
$1.90
Shares
5,633
Total Value
$10,717.91
Owned After
173,999
SEC Form 4
Chief Legal Officer & Corp Sec
Avg Cost/Share
$1.84
Shares
1,054
Total Value
$1,939.36
Owned After
173,999
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$1.84
Shares
462
Total Value
$850.08
Owned After
205,092
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$1.88
Shares
2,689
Total Value
$5,065.54
Owned After
881,275
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$1.82
Shares
895
Total Value
$1,628.90
Owned After
255,371
SEC Form 4
Chief Legal Officer & Corp Sec
Avg Cost/Share
$1.81
Shares
2,247
Total Value
$4,063.25
Owned After
173,999
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$1.81
Shares
2,315
Total Value
$4,180.89
Owned After
205,092
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 28, 2026 | Sell | $3.00 | 2,671 | $8,017.27 | 173,999 | |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 26, 2026 | Sell | $3.00 | 15,085 | $45,262.54 | 173,999 | |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 23, 2026 | Sell | $1.90 | 5,633 | $10,717.91 | 173,999 | |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 22, 2026 | Sell | $1.84 | 1,054 | $1,939.36 | 173,999 | |
| Barton Russell | ABOS | Chief Operating Officer | Jan 22, 2026 | Sell | $1.84 | 462 | $850.08 | 205,092 | |
| Zuga Matt | ABOS | CFO & Chief Business Officer | Jan 22, 2026 | Sell | $1.86 | 1,687 | $3,137.82 | 304,924 | |
| OConnell Daniel Joseph | ABOS | Chief Executive Officer | Jan 22, 2026 | Sell | $1.88 | 2,689 | $5,065.54 | 881,275 | |
| Siemers Eric | ABOS | Chief Medical Officer | Jan 22, 2026 | Sell | $1.82 | 895 | $1,628.90 | 255,371 | |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 21, 2026 | Sell | $1.81 | 2,247 | $4,063.25 | 173,999 | |
| Barton Russell | ABOS | Chief Operating Officer | Jan 21, 2026 | Sell | $1.81 | 2,315 | $4,180.89 | 205,092 |
Compare ABOS vs Leading Stocks
See how ABOS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABOS Acumen Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.